A novel use of temozolomide in a patient with malignant prolactinoma

J Clin Neurosci. 2009 Dec;16(12):1694-6. doi: 10.1016/j.jocn.2009.05.013. Epub 2009 Oct 8.

Abstract

We report a 64-year-old male who presented to our department in 2007 with bitemporal hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and metastatic deposits elsewhere in his neuraxis. He underwent a transphenoidal excision of the large pituitary adenoma which was uncomplicated, although he did suffer from diabetes insipidus post-operatively. He had initially been diagnosed with prolactinoma some years before and had undergone multiple craniotomies to debulk recurrent metastatic lesions. As the patient had already undergone radiotherapy in the past, a novel approach to adjuvant therapy was necessary and he was started on a course of oral chemotherapy, temozolomide, with good results.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pituitary Neoplasms / drug therapy*
  • Prolactinoma / drug therapy*
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide